

Drug Utilization Review Board
(DUR Board)
Meeting – November 12, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. October 14, 2009 DUR Minutes – Vote
 - B. October 15, 2009 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for August 2009
 - B. Retrospective Drug Utilization Review Response for July 2009
 - C. Medication Coverage Activity Audit for October 2009
 - D. Help Desk Activity Audit for October 2009

Items to be presented by Carrie Evans, OHCA Chief Financial Officer, Dr. Muchmore, Chairman:

- 5. OHCA Budget Report**

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 6. Action Item - Vote to Prior Authorize Effient™ – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman:

- 7. Action Item – Vote to Prior Authorize Ulesfia™ – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Edluar™ and Intermezzo® – See Appendix E.**
 - A. Product Summaries
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Antiemetics – See Appendix F.**
 - A. Product Summaries
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Valturna™ – See Appendix G.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **30 Day Notice to Prior Authorize Intuniv™ – See Appendix H.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix I.**

13. **Future Business**
 - A. Anxiolytic Criteria Review
 - B. Antipsychotic Review
 - C. New Product Reviews
 - D. Annual Reviews

14. **Adjournment**